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This document summarizes laboratory guidelines for
the detection, interpretation, and reporting of mater-
nal cell contamination in prenatal analyses. (J Mol
Diagn 2011, 13:7–11; DOI: 10.1016/j.jmoldx.2010.11.013)
Interpretation of prenatal analyses is one of the most
complex areas in genetic testing. Clinicians use invasive
methods that may increase the risk of pregnancy loss, to
obtain chorionic villus samplings (CVS) or amniotic fluid
(AF) for prenatal molecular, cytogenetic, or biochemical
analyses. Though these samples may be small and con-
taminated with maternal tissue or hematopoietic cells,
accurate and timely test results are imperative given the
ramifications associated with these analyses. To provide
a correct result interpretation, the laboratorian must be
confident that the sample used for analyses is of purely
fetal origin. In addition to prenatal diagnosis of inherited
molecular, cytogenetic, or metabolic disorders, maternal
cell contamination (MCC) analysis may also be used in
conjunction with zygosity analysis to rule out the pres-
ence of contaminating maternal or co-fetal material in
multiple gestation pregnancies. Additionally, MCC anal-
ysis can serve as an internal quality assurance measure
to ensure that the biological mother is matched with herconcordant fetus(es), thereby minimizing the possibility
of sample mix-up within a prenatal setting.
Contamination of a fetal or cord blood specimen by ma-
ternal cells is a potential source of error in diagnostic pre-
natal testing. Although contaminating maternal blood can
be visualized in 1% to 2% of amniotic fluid samples and in
up to 38% of pelleted amniocytes following centrifugation,1
the origin of this blood—fetal or maternal—cannot be reli-
ably assessed. Even low levels of contamination that are
below visual detection may negatively impact molecular,
biochemical, or cytogenetic results. Highly sensitive molec-
ular testingmethods have identified the presence of MCC in
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which had no visible evidence of maternal blood.2 MCC
occurs at a significantly lower rate among AF cultures than
in direct (uncultured) AF samples, because culture condi-
tions favor the growth of amniocytes and reduce or elimi-
nate maternal blood cells.3 CVS analysis presumes that the
fetal karyotype/genotype is reflected accurately in the ex-
traembryonic tissues. Contamination of a CVS sample with
cells of maternal origin may result in analysis of the maternal
rather than the fetal karyotype or genotype, especially when
the sample size is small. In CVS and abortus samples, the
culturing process increases the risk of detectable MCC
given the colocalization of maternal and fetal cell lineages in
the placenta. In these situations, MCC can be reduced by
carefully separating the maternal decidua from chorionic
villi before setting up the culture for analysis.4
Professional organizations such as the American Col-
lege of Medical Genetics (http://www.acmg.net/Pages/
ACMG_Activities/stds-2002/g.htm, last accessed August
15, 2010), the Clinical Laboratory Standards Institute
(2006 edition of Standards and Guidelines for Clinical Ge-
netics Laboratories, prenatal testing section G19 first
added in 2003; Molecular Diagnostic Methods for Genetic
Diseases, Approved Guideline—Second Edition, MM1-A2
Vol 26 No 27), and the Clinical Molecular Genetics Soci-
ety (CMGS e-publication 2007: http://www.cmgs.org/BPGs/
pdfs%0current%20bpgs/MCC_08.pdf, last accessed Au-
gust 15, 2010) in the UK have developed standards and
guidelines for cytogenetic and molecular genetic testing
that recommend MCC testing in prenatal diagnosis. How-
ever, a survey performed in 2007 of prenatal diagnostic
practices among 35 laboratories in the US took an evi-
dence-based approach to illustrate a lack of standard-
ization for MCC testing. Only approximately 60% of the
surveyed laboratories performed MCC testing on all pre-
natal samples. There was considerable variability in the
utilization and interpretive criteria for MCC analysis.5 This
report included a comprehensive review of literature rel-
evant to MCC testing practices and concluded that there
is a need for MCC laboratory guidelines to ensure more
standardized, reliable, and accurate results interpretation
in prenatal genetic analyses, for optimal quality assur-
ance within the setting of prenatal diagnosis.
This document provides guidelines to use, interpret, and
report MCC analysis performed within the clinical labora-
tory. These guidelines address the entire testing process
within a clinical laboratory, from preanalytical, through the
analytical (to include technical and interpretative) and post-
analytical (reporting) phases of analysis. Together with
good laboratory practices and existing standards and
guidelines for molecular genetic testing of heritable dis-
eases, these guidelines can help provide accurate genetic
information and minimize the potential of diagnostic error.
Preanalytical Guidelines
1. To determine the pure fetal origin of all prenatal spec-
imens undergoing genetic analysis, it is recommendedthat MCC analysis be performed in parallel with diagnos-
tic testing, regardless of the genetic disorder or its mode
of inheritance.
2. The need for a maternal specimen (typically blood or
buccal) for concurrent MCC analysis should be commu-
nicated to the treating clinicians by the laboratory before
prenatal specimen collection.
3. All pertinent intake information including clinical,
family, and testing history, should be provided to the
testing laboratory, along with the prenatal sample.
4. Appropriate disclosure of biological relationships
and representation of maternal parentage are required
(for example: a gamete donor or surrogate pregnancy).
5. Information regarding multiple gestations should be
available to the laboratory, along with the prenatal sam-
ple, due to the risk of potential co-fetal contamination
from a twin.
6. Only a maternal peripheral blood or buccal sample
is strictly required for MCC testing. Paternal samples are
not helpful for MCC analysis.
7. Acceptable specimen types for prenatal analysis
include directly obtained, uncultured AF and CVS, cul-
tured AF and CVS, cord blood, peripheral umbilical blood
specimens, and products of conception.
8. The median quantity of material requested for direct
AF testing is 12 ml and 5 to 10 mg of cleaned, isolated
CVS tissue.5 However, due to the precious nature of
these prenatal specimens, testing on samples with vol-
umes below the minimum requested amount may be
attempted depending on the policies and practices of the
testing laboratory. In such instances, if the results follow-
ing prenatal analysis are either inconclusive or unclear, it
is strongly recommended to confirm the test results on a
backup cultured specimen. A fully adherent monolayer of
cultured AF or CVS cells at a confluency of at least 75%
is preferred for testing. Cultured cells at low confluency or
cultures containing nonadherent, dislodged nonviable
cells should not be appropriate for testing.
9. Specific prenatal specimen information to be re-
corded by the testing laboratory should include: the sam-
ple type, date of collection, collection container types,
sample condition on arrival, tube label check, color of the
cell culture media, degree of confluency, and the pres-
ence and extent of blood and/or decidua in uncultured
amniotic fluid or CVS specimens. Laboratories should
have procedures to ensure that every CVS specimen is
thoroughly examined under a dissecting microscope to
remove any contaminating maternal decidua before
setting up both direct as well as long-term CVS cul-
tures. Coordination between the testing laboratory and
the cytogenetics laboratory may be needed to ensure
this process.
10. Specimen requirements depend on the testing
method used. For instance, a smaller sample amount is
required for a PCR-based assay versus Southern blot
analysis. Also, the sample size obtained may be propor-
tional to gestational age. In general, the risk of MCC is
greater early in gestation, because of the relative paucity
of fetal cells compared to maternal cells. Robust extrac-
tion methods must be used to ensure adequate yield of
DNA from prenatal specimens.
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repeat or confirmatory testing if MCC is detected in an
uncultured specimen. The backup cultures must remain
available until the testing is completed and results are
reported to the ordering physician. Reduced turnaround
time and decreased cost of analysis are advantages to
testing direct AF specimens; however, there is a greater
possibility of contamination with maternal hematopoietic
cells. Cultured AF cells, on the other hand, are much
more likely to represent a homogeneous specimen type
reflecting pure fetal origin due to an absence of coexist-
ing contamination with cells of maternal hematopoietic
origin. Maternal blood cells senesce during culture and
are not expected to proliferate.6 Although prolonged cul-
ture may allow overgrowth of maternal fibroblasts and
epithelial cells, potentially leading to detectable MCC,
discarding the first draw of amniotic fluid samples can
reduce this possibility.7
12. Every effort should be made to include the prenatal
sample(s) in the earliest available assay setup and to
prioritize the prenatal samples into testing if clinically
warranted.
13. It is important that only one prenatal test sample be
handled at any one time to ensure accuracy and prevent
a potential mix-up of samples at this stage of analysis.
14. The laboratory performing the diagnostic prenatal
analysis should preferably also perform the MCC testing.
This approach allows the laboratory to provide a compre-
hensive and centralized result interpretation. This in turn
helps to improve turnaround time and ensures quality
assurance of the entire process in one laboratory.
Technical Guidelines
1. MCC testing should be performed on DNA extracted
from the same sample or subsample, culture or subculture,
that was used for concurrent clinical diagnostic testing.
2. Maternal and prenatal specimens should be tested
and analyzed for MCC concurrently within the same anal-
ysis to allow for a direct comparison of results.
3. A variety of commercial DNA genotyping assays are
available for the purpose of identity testing. The perfor-
mance characteristics of these assaysmust be validated for
the intended purpose of MCC studies in each laboratory
before implementation into clinical testing. The basic
premise of these assays is the comparison of highly poly-
morphic short tandem repeat/microsatellite loci between the
maternal and fetal DNA samples following PCR and size
separation, to assess the risk of MCC in the fetal sample.
4. Tetranucleotide/pentanucleotide markers are prefer-
able monitors of MCC over smaller (eg, dinucleotide)
repeat markers due to the superior fidelity, robustness of
PCR amplification, accurate measurement of repeat units
by fragment analysis, distinguishable alleles with a high
discriminative capacity, and intergenerational stability
among individuals in the general population.
5. The MCC analysis should use a sufficient number of
markers to accurately rule out MCC at the level of sensi-
tivity previously determined by the laboratory during its
initial MCC assay validation process. In general, MCCassays that include a larger number of polymorphic
markers are preferable because of the increased likeli-
hood of having included multiple informative markers
(that clearly demonstrate an unshared allele between
mother and fetus) and because markers can differ in their
informativeness when the level of MCC is at or near the
assay’s limit of detection. Using only a couple of markers
may provide a false sense of security around apparently
absent MCC.
6. If using capillary electrophoresis technology, we
recommend that peak height and signal-to-noise ratio
thresholds be monitored within the testing laboratory to
reliably assess percentage MCC detectable following ex-
traction and molecular amplification. Variation in assay
performance, attributable to factors such as input DNA
concentrations and analyzer specifications resulting in
weak genotype data (such as low peak heights), may
affect MCC assay sensitivity.
7. PCR stutter peaks (caused by replication slippage
during PCR amplification) that are the size of the repeat
unit of a maternal allele should be considered noninfor-
mative for MCC studies because low-level MCC may be
obscured in this setting. A flat baseline on the fetal sam-
ple electropherogram in the region of interest enables the
reviewer to detect even a small peak of maternal origin.
8. Identical allelic markers between mother and fetus
are uninformative for MCC. It is recommended that two to
three informative microsatellite markers reflecting clearly
definable, separate maternal and fetal genotypes from
among a panel of approximately 7 to 10 markers be used
to assess the presence of MCC in a prenatal sample.
9. By using the peak heights or area under the curve for
each primary allele peak, the proportion of a contaminating
maternal allele to a noncontaminating, nonshared fetal allele
can be estimated for each informative marker. The calcu-
lated percentage across all informative markers would be
expected to approximately correlate with the extent of ma-
ternal contamination within a prenatal sample.
10. If supplementary evidence from the clinical prena-
tal test is taken into consideration to rule out MCC, it is
imperative that both the maternal and fetal specimens be
tested in the same molecular assay. This allows a direct
comparison of results, thereby excluding the possibility of
allele dropout attributed to sequence variants and/or
polymorphisms that might affect the analysis and the
resulting interpretation. For example, if the fetus is nega-
tive for the maternal mutation in the diagnostic test, then
this finding could be considered as one informative
marker for the purpose of ruling out MCC, as long as both
the maternal and fetal specimens are tested by the same
diagnostic assay methodology.
11. Ideally, the testing laboratory would know the val-
idated sensitivity of each prenatal analysis (based on
methodology) to varying amounts of MCC and its effect
on result interpretation. A validated MCC assay that is
more sensitive than the clinical diagnostic assay will help
ensure that low levels of contamination not detectable by
an MCC assay do not affect the clinical test result inter-
pretation. Performing both the diagnostic prenatal analy-
sis and MCC testing within the same laboratory allows for
10 Nagan et al
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the sensitivity of each assay.
12. At least 5%MCCmust be routinely detectable by the
clinical laboratory. This percentage is recommended as the
upper limit based on the fact that erythrocyte admixture of
just a few percent is readily visible by eye, and that incorrect
interpretation of a PCR-based diagnostic prenatal test has
been reported even at a level of 1% to 2% MCC,6 with
increasing likelihood at higher percentages.
Interpretive Guidelines
1. Inheritance of a marker presenting as a null allele due
to allele dropout and/or a deletion within a marker may
cause an apparent discordant result between the mother
and the fetus at any particular locus.8 Somatic changes in
allele repeat units of the fetus due to de novo or post-
zygotic mutations are another reason for discordance at
single marker loci. If only one discordant marker (a null
allele or somatic mutation) is present between the mater-
nal and fetal specimen, and concordance between the
maternal specimen and the fetus at all other loci is ob-
served, the identity of the maternal specimen can often
still be reliably assured. It is recommended that assays
for MCC include a sufficient number of markers to mini-
mize the risk of mismatching a maternal/fetal pair. Inclu-
sion of additional markers on an as-needed basis, to
enhance the informativeness of the assay, may be useful
in such situations.
2. Organizations such as the American Association of
Blood Banks provide annual survey updates for the fre-Figure 1. A recommended testing algorithm for prenatal analyses.quencies of null and de novo mutation rates among short
tandem repeat and variable number of tandem repeat
markers. This information could be useful in marker se-
lection and/or reconciling an observed discordant result
between the maternal and fetal alleles for any particular
marker/locus. (http://www.aabb.org/Content/Accreditation/
Parentage_Testing_Accreditation_Program/Relationship_
Testing_Annual_Reports/reports.htm, last accessed August
15, 2010).
3. A high risk for misinterpretation of the result of a
fetus and a biological parent occurs within the setting of
a gamete donor or surrogate pregnancy. In this scenario,
discordance between the maternal (ie, surrogate mother)
and fetal specimen at multiple loci would be observed.
Such findings should alert the laboratory to initiate further
investigation(s) to determine the origin of discordance. If
the information regarding a gamete donor or a surrogate
pregnancy is confirmed, the MCC assay would still be
valid, and the presence of any contaminating secondary
maternal alleles (of surrogate origin) would still be ex-
pected to raise suspicion of sample contamination.
Reporting Guidelines
1. The prenatal diagnostic results should not be released
before the MCC analysis is completed.
2. MCC assays may incidentally identify or be sugges-
tive of the presence of a chromosomal aneuploidy. The
MCC assay serves to answer a different clinical inquiry
and should not be used to report the presence of an
aneuploidy, or copy number variants, without confirma-
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purpose.
3. Multiple gestation pregnancies should be acknowl-
edged on the report along with a caveat regarding the
potential impact of fetal sampling on the accuracy of
MCC results.
4. It should be acknowledged that the absence or
presence of MCC in the tested specimen does not rule
in/out the presence or absence of contamination in an-
other specimen or subspecimen obtained from the fetus
under consideration.
5. The sensitivity of the MCC assay should be indi-
cated on all issued MCC reports.
6. If no MCC is detected, the accuracy of the prenatal
test result can be reliably assured at the level of detection
of the MCC assay. The presence of very small peaks,
possibly indicating low-level MCC at or below the vali-
dated level of detection for the MCC assay or below the
threshold of sensitivity of the clinical assay, may require
acknowledgment on the reports. Comments in the con-
text of such reports may include phrases such as “sig-
nificant maternal cell contamination not detected,” or
“maternal cell contamination is unlikely to have interfered
with the reported fetal result.” If significant MCC is de-
tected at a level expected to interfere with the prenatal
test result, a repeat specimen should be requested,
and it should be clearly stated that no result is avail-
able. Options for further analysis may be provided as
appropriate. Follow-up by direct communication with
the referring clinician or genetic counselor may also be
considered.
7. Final prenatal test results should be reported to the
referring physician in conjunction with the MCC report.
Conclusions
The guidelines provided are intended to assist laborato-
ries in developing and optimizing prenatal MCC analysis,
to provide prenatal genetic testing results of high quality
and to enhance accurate result interpretation. These
guidelines are expected to evolve and undergo further
additions/modifications as emerging prenatal detection
technologies such as circulating fetal DNA in maternal
plasma and other technologies for molecular, cytoge-
netic, and biochemical diagnosis are developed. We rec-ommend that MCC testing be performed on all diagnostic
prenatal samples without exception and regardless of the
mode of inheritance of the potentially underlying condi-
tion. Further, our recommendation is that MCC testing
should be the standard of care for prenatal diagnosis
using methods of molecular mutation analysis and for
molecular cytogenetic applications such as array com-
parative genomic hybridization. Consideration of MCC
studies for those CVS cytogenetic studies that do not
include results from a direct culture but show a female
(XX) karyotype, and for all prenatal biochemical analyte
assays is strongly recommended, given the serious im-
plications of inaccurate results in the prenatal setting.
Finally, the included testing algorithm (Figure 1) could be
followed or adapted to the specific capabilities and prac-
tice of clinical diagnostic laboratories.
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